Physician profile
Richard Cho
NPI 1316110125
$4,442.68
in general payments reported to CMS, 2019-2025
40 companies · $954 in 2025
The $954 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $610 · 2020: $484 · 2021: $378 · 2022: $588 · 2023: $534 · 2024: $896 · 2025: $954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,383.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $990.81 | 2019-2022 | |
| Abbvie INC. | $723.54 | 2022-2025 | Qulipta, Ubrelvy |
| Jazz Pharmaceuticals INC. | $407.13 | 2019-2025 | |
| Harmony Biosciences LLC | $399.65 | 2023-2025 | Wakix |
| Lundbeck LLC | $194.02 | 2019-2025 | Vyepti |
| Novartis Pharmaceuticals Corporation | $156.51 | 2019-2024 | |
| Pfizer INC. | $134.68 | 2023-2025 | |
| Axsome Therapeutics, INC. | $129.81 | 2023-2025 | Sunosi, Symbravo |
| Lilly USA, LLC | $118.16 | 2023-2025 | Amyvid, Emgality, Reyvow |
| Merz Pharmaceuticals, LLC | $96.49 | 2024-2025 | Inbrija, Xeomin, Ampyra |
| Nuvasive, INC. | $91.50 | 2020 | |
| Avadel Cns Pharmaceuticals, LLC | $86.08 | 2024-2025 | Lumryz |
| Allergan, INC. | $71.57 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $68.97 | 2019 | |
| Eisai INC. | $64.21 | 2021-2025 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Cho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.